Julia Rotow, MD

Julia Rotow, MD

Dana-Farber Cancer Institute

Latest Videos

Time Toxicity, CNS Risk, and Sequencing Strategy in EGFR-Mutant NSCLC - OncUpdates featuring Dr. Julia Rotow, Dr. Fawzi Abu Rous, Dr. Sarah Goldberg, and Dr. Susan Scott discussing recent advances in.

Roundtable

03/19/2026

Ep. 3: Time Toxicity, CNS Risk, and Sequencing Strategy in EGFR-Mutant NSCLC

Eric Singhi, MDSarah Goldberg, MD, MPHFawzi Abu Rous, MDJulia Rotow, MDSusan Scott, MD
Proactive toxicity management and CNS control in EGFR-mutant NSCLC discussed by leading oncologists at OncUpdates conference. Expert insights on personalized treatment strategies.

Roundtable

03/17/2026

Ep. 2: Clinical Insights: Proactive Toxicity Management and CNS Control in EGFR-Mutant NSCLC

Eric Singhi, MDSarah Goldberg, MD, MPHSusan Scott, MDFawzi Abu Rous, MDJulia Rotow, MD
OS Benefit and Patient-Centered Delivery Advances in EGFR-Positive NSCLC, featuring Dr. Eric Singhi, Dr. Julia Rotow, Dr. Susan Scott, Dr. Sarah Goldberg, and Dr. Fawzi Abu Rous discussing recent onco.

Roundtable

03/14/2026

Ep. 1: OS Benefit and Patient-Centered Delivery Advances in EGFR-Mutant NSCLC

Eric Singhi, MDSusan Scott, MDSarah Goldberg, MD, MPHFawzi Abu Rous, MDJulia Rotow, MD